Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2861205-06-1
Molecular formula
C92H129FN14O17
Molecular weight
1722.1 g/mol
Drug class
PCSK9-targeting small interfering RNA (siRNA)RNA interference lipid-lowering therapy
Mechanism of action
A GalNAc-conjugated siRNA targets PCSK9 mRNA in hepatocytes and promotes RISC-mediated degradation, reducing PCSK9 protein and increasing hepatic LDL receptor recycling and LDL-cholesterol clearance.
Indications / reported uses
Treatment of adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, as an adjunct to diet and other lipid-lowering therapies under the US LIPIDRA indication (approved 2026); dosing and label-specific eligibility apply
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Enlicitide Decanoate Environmental Risk Assessment (ERA) (the Enlicitide Decanoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.